Evidence that von Willebrand Factor is Not Required for the Clotting of Plasma in the Presence of Platelets and Kaolin (Hardisty-Hutton Test)

Summary

Antihemophilic factor (AHF) essentially free of von Willebrand factor (vWF) was used to determine whether vWF affected the coagulant activity of AHF in a kaolin-activated system using platelet-rich plasma. The AHF was prepared by sequential chromatography on solid-phase polyelectrolyte (PE E-5), and on Sepharose CL-4B in the presence of a high concentration of CaCl₂. Residual traces of vWF antigen were removed by affinity chromatography with immobilized anti-vWF IgG. The essentially vWF-free AHF corrected the clotting defect of plasma from three patients with severe von Willebrand’s disease (vWD) as measured by the kaolin-activated clotting time in the presence of normal or vWD platelets (Hardisty-Hutton test). Addition of hemophilic plasma as a source of vWF did not cause additional improvement, nor did a potent antibody to vWF raised in rabbits inhibit the ability of AHF to shorten the clotting time of vWD plasma. Thus we found no evidence that vWF is necessary for AHF to function in the coagulation of recalcified kaolin-activated vWF-deficient platelet-rich plasma.

Keywords

von Willebrand factor - Antihemophilic factor - Blood clotting - Factor VIII

• References

• 1 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13
• 2 Zucker MB, Soberano ME, Johnson AJ, Fulton AJ, Kowalski S, Adler M. The in vitro association of antihemophilic factor and von Willebrand factor. Thromb Haemostas 1983; 49: 37-41
• 3 Owen WG, Wagner RH. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents. Thrombos Diathes Haemorrh 1972; 27: 502-515
• 4 Rick ME, Hoyer LW. Immunologic studies of antihemophilic factor (AHF, factor VIII). V. Immunologic properties of AHF subunits produced by salt dissociation. Blood 1973; 42: 737-747
• 5 Weiss HJ, Hoyer LW. von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science 1973; 182: 1149-1151
• 6 Caen JP, Levy-Toledano S. Interaction between platelets and von Willebrand factor provides a new scheme for primary haemostasis. Nature 1973; 244: 159-160
• 7 Weiss HJ, Tschopp TB, Baumgartner HR, Sussman II, Johnson MM, Egan JJ. Decreased adhesion of giant (Bemard-Soulier) platelets to subendothelium. Am J Med 1974; 57: 920-925
• 8 Bithell TC, Parekh SJ, Strong RR. Platelet-function studies in the Bernard-Soulier syndrome. Ann N Y Acad Sci 1972; 201: 145-160
• 9 Moake JL, Olson JD, Troll JH, Tang SS, Funicella T, Peterson DM. Binding of radioiodinated human von Willebrand factor to Bernard-Soulier thrombasthenic and von Willebrand’s disease platelets. Thromb Res 1980; 19: 21-27
• 10 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61: 99-109
• 11 Vukovich T, Roller E, Doleschel W. Low-molecular weight factor VIII requires a cofactor for its procoagulant activity. Thromb Res 1980; 19: 503-511
• 12 Johnson AJ, Macdonald VE, Semar M, Fields JE, Schuck J, Lewis C, Brind J. Preparation of the major plasma fractions by solid-phase polyelectrolytes. J Lab Clin Med 1978; 92: 194-210
• 13 Johnson AJ, Soberano ME, Kowalski S, Fulton A, MacDonald VE, Semar M. Separation of AHF from vWF by solid-phase polyelectrolytes (PE); further evidence for their separate identity. Thromb Haemostas 1981; 46: 255 (Abstr)
• 14 Hardisty RM, Hutton RA. The kaolin clotting time of platelet-rich plasma: a test of platelet factor-3 availability. Br J Haematol 1965; 11: 258-268
• 15 Amrani DL, Mosesson MW, Hoyer LW. Distribution of plasma fibronectin (cold-insoluble globulin) and components of the factor VIII complex after heparin-induced precipitation of plasma. Blood 1982; 59: 657-663
• 16 Newman J, Johnson AJ, Karpatkin MH, Puszkin S. Method for the production of clinically effective intermediate- and high-purity factor VIII concentrates. Br J Haematol 1971; 21: 1-20
• 17 Ness PM, Perkins HA. A Simple enzyme-immunoassay (EIA) test for factor VUI-related antigen (VIII_agn). Thromb Haemostas 1979; 42: 848-854
• 18 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-847
• 19 Zucker MB, Owen J. Non-decalcified barium sulfate-adsorbed plasma. A potentially useful reagent for studying blood clotting, platelets or complement Thromb Haemostas 1982; 47: 182-184
• 20 Tran TH, Marbet GA, Duckert F. Rabbit antibodies against the procoagulant activity (VIII: C) of human factor VIII. Thromb Haemostas 1981; 46: 699-705